Inefficient CAR-proximal signaling blunts antigen sensitivity.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
08 2020
Historique:
received: 03 07 2019
accepted: 26 05 2020
pubmed: 8 7 2020
medline: 5 11 2020
entrez: 8 7 2020
Statut: ppublish

Résumé

Rational design of chimeric antigen receptors (CARs) with optimized anticancer performance mandates detailed knowledge of how CARs engage tumor antigens and how antigen engagement triggers activation. We analyzed CAR-mediated antigen recognition via quantitative, single-molecule, live-cell imaging and found the sensitivity of CAR T cells toward antigen approximately 1,000-times reduced as compared to T cell antigen-receptor-mediated recognition of nominal peptide-major histocompatibility complexes. While CARs outperformed T cell antigen receptors with regard to antigen binding within the immunological synapse, proximal signaling was significantly attenuated due to inefficient recruitment of the tyrosine-protein kinase ZAP-70 to ligated CARs and its reduced concomitant activation and subsequent release. Our study exposes signaling deficiencies of state-of-the-art CAR designs, which presently limit the efficacy of CAR T cell therapies to target tumors with diminished antigen expression.

Identifiants

pubmed: 32632291
doi: 10.1038/s41590-020-0719-0
pii: 10.1038/s41590-020-0719-0
doi:

Substances chimiques

Antigens, Neoplasm 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

848-856

Subventions

Organisme : Austrian Science Fund FWF
ID : W 1224
Pays : Austria

Commentaires et corrections

Type : CommentIn

Références

Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).
pubmed: 11753365 doi: 10.1038/nbt0102-70
Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676–684 (2004).
pubmed: 14961035 doi: 10.1038/sj.leu.2403302
Finney, H. M., Lawson, A. D. G., Bebbington, C. R. & Weir, A. N. C. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791–2797 (1998).
pubmed: 9743337
Srivastava, S. & Riddell, S. R. Engineering CAR-T cells: design concepts. Trends Immunol. 36, 494–502 (2015).
pubmed: 26169254 pmcid: 4746114 doi: 10.1016/j.it.2015.06.004
Huang, J. et al. A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4
pubmed: 24120362 doi: 10.1016/j.immuni.2013.08.036
Irvine, D. J., Purbhoo, M. A., Krogsgaard, M. & Davis, M. M. Direct observation of ligand recognition by T cells. Nature 419, 845–849 (2002).
pubmed: 12397360 doi: 10.1038/nature01076
Purbhoo, M. A., Irvine, D. J., Huppa, J. B. & Davis, M. M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5, 524–530 (2004).
pubmed: 15048111 doi: 10.1038/ni1058
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
pubmed: 25317870 pmcid: 4267531 doi: 10.1056/NEJMoa1407222
Turtle, C. J. et al. CD19 CAR–T cells of defined CD4
pubmed: 27111235 pmcid: 4887159 doi: 10.1172/JCI85309
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
pubmed: 29385370 pmcid: 5996391 doi: 10.1056/NEJMoa1709866
Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018).
pubmed: 29155426
Huppa, J. B. et al. TCR–peptide–MHC interactions in situ show accelerated kinetics and increased affinity. Nature 463, 963–967 (2010).
pubmed: 20164930 pmcid: 3273423 doi: 10.1038/nature08746
Douglass, A. D. & Vale, R. D. Single-molecule microscopy reveals plasma membrane microdomains created by protein–protein networks that exclude or trap signaling molecules in T cells. Cell 121, 937–950 (2005).
pubmed: 15960980 pmcid: 2851620 doi: 10.1016/j.cell.2005.04.009
Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153–3164 (2013).
pubmed: 23620405 pmcid: 3804130 doi: 10.1158/1078-0432.CCR-13-0330
Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489–503.e8 (2019).
pubmed: 30889382 pmcid: 6450658 doi: 10.1016/j.ccell.2019.02.003
Alberola-Ila, J., Takaki, S., Kerner, J. D. & Perlmutter, R. M. Differential signaling by lymphocyte antigen receptors. Annu. Rev. Immunol. 15, 125–154 (1997).
pubmed: 9143684 doi: 10.1146/annurev.immunol.15.1.125
Chan, A. C., Iwashima, M., Turck, C. W. & Weiss, A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR ζ chain. Cell 71, 649–662 (1992).
pubmed: 1423621 doi: 10.1016/0092-8674(92)90598-7
Bunnell, S. C. et al. T cell receptor ligation induces the formation of dynamically regulated signaling assemblies. J. Cell Biol. 158, 1263–1275 (2002).
pubmed: 12356870 pmcid: 2173229 doi: 10.1083/jcb.200203043
Pores-Fernando, A. T. & Zweifach, A. Calcium influx and signaling in cytotoxic T-lymphocyte lytic granule exocytosis. Immunol. Rev. 231, 160–173 (2009).
pubmed: 19754896 doi: 10.1111/j.1600-065X.2009.00809.x
Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8
pubmed: 25520398 doi: 10.4049/jimmunol.1402346
Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189–2201 (2017).
pubmed: 28676342 pmcid: 5589087 doi: 10.1016/j.ymthe.2017.06.008
Potter, T. A., Bluestone, J. A. & Rajan, T. V. A single amino acid substitution in the α3 domain of an H-2 class I molecule abrogates reactivity with CTL. J. Exp. Med. 166, 956–966 (1987).
pubmed: 3498790 doi: 10.1084/jem.166.4.956
Baskar, S., Wiestner, A., Wilson, W. H., Pastan, I. & Rader, C. Targeting malignant B cells with an immunotoxin against ROR1. MAbs 4, 349–361 (2012).
pubmed: 22531447 pmcid: 3355487 doi: 10.4161/mabs.19870
Yang, J. et al. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE 6, e21018 (2011).
pubmed: 21698301 pmcid: 3115963 doi: 10.1371/journal.pone.0021018
Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125–135 (2015).
pubmed: 25212991 doi: 10.1158/2326-6066.CIR-14-0127
Choudhuri, K., Wiseman, D., Brown, M. H., Gould, K. & van der Merwe, P. A. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 436, 578–582 (2005).
pubmed: 16049493 doi: 10.1038/nature03843
Stewart-Jones, G. et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc. Natl Acad. Sci. USA 106, 5784–5788 (2009).
pubmed: 19307587 doi: 10.1073/pnas.0901425106 pmcid: 2667008
Maus, M. V. et al. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol. Ther. Oncolytics 3, 16023 (2016).
doi: 10.1038/mto.2016.23
Maus, M. V. et al. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32, 189–225 (2014).
pubmed: 24423116 pmcid: 4533835 doi: 10.1146/annurev-immunol-032713-120136
Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).
pubmed: 25939063 pmcid: 4458184 doi: 10.1038/nm.3838
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P. & Abken, H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J. Immunol. 173, 7647–7653 (2004).
pubmed: 15585893 doi: 10.4049/jimmunol.173.12.7647
Chmielewski, M., Hombach, A. A. & Abken, H. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther. 18, 62–72 (2011).
pubmed: 20944680 doi: 10.1038/gt.2010.127
Iwashima, M., Irving, B. A., van Oers, N. S., Chan, A. C. & Weiss, A. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science 263, 1136–1139 (1994).
pubmed: 7509083 doi: 10.1126/science.7509083
Pelosi, M. et al. Tyrosine 319 in the interdomain B of ZAP-70 is a binding site for the Src homology 2 domain of Lck. J. Biol. Chem. 274, 14229–14237 (1999).
pubmed: 10318843 doi: 10.1074/jbc.274.20.14229
Katz, Z. B., Novotná, L., Blount, A. & Lillemeier, B. F. A cycle of Zap70 kinase activation and release from the TCR amplifies and disperses antigenic stimuli. Nat. Immunol. 18, 86–95 (2017).
pubmed: 27869819 doi: 10.1038/ni.3631
Varma, R., Campi, G., Yokosuka, T., Saito, T. & Dustin, M. L. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity 25, 117–127 (2006).
pubmed: 16860761 pmcid: 1626533 doi: 10.1016/j.immuni.2006.04.010
Ruella, M. & Maus, M. V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 14, 357–362 (2016).
pubmed: 27761200 pmcid: 5061074 doi: 10.1016/j.csbj.2016.09.003
Evans, A. G. et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205–209 (2015).
pubmed: 26084925 doi: 10.1111/bjh.13562
Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504–1506 (2018).
pubmed: 30275569
Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263 (2011).
pubmed: 21653320 pmcid: 3152493 doi: 10.1182/blood-2011-02-337360
Zacharias, D. A., Violin, J. D., Newton, A. C. & Tsien, R. Y. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science 296, 913–916 (2002).
pubmed: 11988576 doi: 10.1126/science.1068539
Hudecek, M. et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116, 4532–4541 (2010).
pubmed: 20702778 pmcid: 2996114 doi: 10.1182/blood-2010-05-283309
Brown, C. E. et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J. Immunol. Methods 297, 39–52 (2005).
pubmed: 15777929 doi: 10.1016/j.jim.2004.11.021
Klesmith, J. R., Wu, L., Lobb, R. R., Rennert, P. D. & Hackel, B. J. Fine epitope mapping of the CD19 extracellular domain promotes design. Biochemistry 58, 4869–4881 (2019).
pubmed: 31702909 doi: 10.1021/acs.biochem.9b00808
Garboczi, D. N., Hung, D. T. & Wiley, D. C. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl Acad. Sci. USA 89, 3429–3433 (1992).
pubmed: 1565634 doi: 10.1073/pnas.89.8.3429 pmcid: 48881
Clements, C. S. et al. The production, purification and crystallization of a soluble heterodimeric form of a highly selected T-cell receptor in its unliganded and liganded state. Acta Crystallogr. D Biol. Crystallogr. 58, 2131–2134 (2002).
doi: 10.1107/S0907444902015482
Axmann, M., Schütz, G. J. & Huppa, J. B. Single molecule fluorescence microscopy on planar supported bilayers. J. Vis. Exp. e53158 (2015).
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
pubmed: 22743772 doi: 10.1038/nmeth.2019
Schindelin, J., Rueden, C. T., Hiner, M. C. & Eliceiri, K. W. The ImageJ ecosystem: an open platform for biomedical image analysis. Mol. Reprod. Dev. 82, 518–529 (2015).
pubmed: 26153368 pmcid: 5428984 doi: 10.1002/mrd.22489
Gao, Y. & Kilfoil, M. L. Accurate detection and complete tracking of large populations of features in three dimensions. Opt. Express 17, 4685–4704 (2009).
pubmed: 19293898 doi: 10.1364/OE.17.004685
Wieser, S., Moertelmaier, M., Fuertbauer, E., Stockinger, H. & Schütz, G. J. (Un)confined diffusion of CD59 in the plasma membrane determined by high-resolution single molecule microscopy. Biophys. J. 92, 3719–3728 (2007).
pubmed: 17325009 pmcid: 1853144 doi: 10.1529/biophysj.106.095398
Roe, M. W., Lemasters, J. J. & Herman, B. Assessment of Fura-2 for measurements of cytosolic free calcium. Cell Calcium 11, 63–73 (1990).
pubmed: 2191782 doi: 10.1016/0143-4160(90)90060-8
Lowe, D. G. Distinctive image features from scale-invariant keypoints. Int. J. Comput. Vis. 60, 91–110 (2004).
doi: 10.1023/B:VISI.0000029664.99615.94
Jaqaman, K. et al. Robust single-particle tracking in live-cell time-lapse sequences. Nat. Methods 5, 695–702 (2008).
pubmed: 18641657 pmcid: 2747604 doi: 10.1038/nmeth.1237
Tinevez, J.-Y. et al. TrackMate: an open and extensible platform for single-particle tracking. Methods 115, 80–90 (2017).
pubmed: 27713081 doi: 10.1016/j.ymeth.2016.09.016

Auteurs

Venugopal Gudipati (V)

Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria.

Julian Rydzek (J)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Iago Doel-Perez (I)

Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria.

Vasco Dos Reis Gonçalves (VDR)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Lydia Scharf (L)

Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria.
Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Sebastian Königsberger (S)

Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria.
Roche Diagnostics GmbH, Penzberg, Germany.

Elisabeth Lobner (E)

Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.

Renate Kunert (R)

Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.

Hermann Einsele (H)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Hannes Stockinger (H)

Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria.

Michael Hudecek (M)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany. Hudecek_M@ukw.de.

Johannes B Huppa (JB)

Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria. johannes.huppa@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH